Anyone interested in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) should probably be aware that the Co-Founder, Chad Robins, recently divested US$167k worth of shares in the company, at an average price of US$3.43 each. However, the silver lining is that the sale only reduced their total holding by 1.9%, so we're hesitant to read anything much into it, on its own.

Adaptive Biotechnologies Insider Transactions Over The Last Year

The Chief Financial Officer, Tycho Peterson, made the biggest insider sale in the last 12 months. That single transaction was for US$272k worth of shares at a price of US$7.16 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$3.45). So it may not tell us anything about how insiders feel about the current share price.

Insiders in Adaptive Biotechnologies didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Adaptive Biotechnologies

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Adaptive Biotechnologies insiders own about US$15m worth of shares. That equates to 3.1% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Adaptive Biotechnologies Tell Us?

Insiders sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Adaptive Biotechnologies. In terms of investment risks, we've identified 2 warning signs with Adaptive Biotechnologies and understanding them should be part of your investment process.

But note: Adaptive Biotechnologies may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.